Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 1,3-butylene Glycol
2. Butylene Glycol
1. Butane-1,3-diol
2. 107-88-0
3. 1,3-butylene Glycol
4. Butylene Glycol
5. 1,3-dihydroxybutane
6. Methyltrimethylene Glycol
7. 1,3 Butylene Glycol
8. 1,3-butandiol
9. Beta-butylene Glycol
10. 1-methyl-1,3-propanediol
11. (rs)-1,3-butandiol
12. 1,3-butylenglykol
13. Caswell No. 128gg
14. Nsc-402145
15. Dtxsid8026773
16. 3xus85k0ra
17. Brn 1731276
18. Chebi:52683
19. Ai3-11077
20. Dtxcid306773
21. Nsc402145
22. Herbal Moxibustion
23. Chinese Medicine Patch
24. Mummy Mask
25. Refchem:54584
26. Glytoucan:g07075bd
27. 3% Hyaluronic Acid Serum
28. Natural Oriental Herb Care
29. Srripo Biotin Hair Treatment
30. Acmeros Lubricant X0026f3541
31. Shizhentaiyitang Moxibustion Patch
32. Linglongjiuhuo Linglong Moxibustion
33. Qizhouguai Chinese Medicine Patch
34. G07075bd
35. Vshell Hair Treatment Biotin Conditioner
36. 3ce Super Slim Pen Eye Liner Black
37. 3ce Super Slim Pen Eye Liner Brown
38. Water-based Personal Lubricant, Acvioo 001
39. 3ce Super Slim Pen Eye Liner Light Brown
40. 3ce Super Slim Pen Eye Liner Burgundy Brown
41. Linglongjiuhuo Linglong Moxibustion Wormwood Moxibustion Patch
42. 203-529-7
43. (+/-)-1,3-butanediol
44. 1,3-butanodiol
45. Mfcd00004554
46. .beta.-butylene Glycol
47. Bd
48. Nsc 402145
49. ( Inverted Exclamation Marka)-1,3-butanediol
50. Butanediol,1,3-
51. Nsc6966
52. 1,3-butandiol [german]
53. 1,3-butane Diol
54. Cas-107-88-0
55. 1,3-butylenglykol [german]
56. Hsdb 153
57. 1,3-butanediol, (r)-
58. 1,3-butanediol, (s)-
59. Einecs 203-529-7
60. Unii-3xus85k0ra
61. (s)-(+)-1,3-butylene Glycol
62. B-butylene Glycol
63. 1.3-butanediol
64. 1,3 -butanediol
65. Utane-1,3-diol
66. Butylene Glycol (butane-1,3-diol)
67. Dl-1,3-butanediol
68. R-butane-1,3-diol
69. Butylene Glycol (nf)
70. Racemic 1,3-butanediol
71. Butanediol,3-
72. 1,3-butanediol, Dl-
73. (rs)-1,3-butanediol
74. 1,3-butanediol 100 Microg/ml In Acetonitrile
75. Ec 203-529-7
76. Schembl8176
77. (+/-) 1,3 Butandiol
78. (+/-)-1,3-butandiol
79. 1,3-butanediol (standard)
80. Schembl19355
81. Schembl94448
82. Butylene Glycol [ii]
83. 0-01-00-00477 (beilstein Handbook Reference)
84. Schembl331940
85. Schembl739193
86. Orb1298236
87. Schembl1044624
88. Schembl1547914
89. Schembl1749188
90. Schembl2688282
91. Schembl8023169
92. (.+/-.)-1,3-butanediol
93. Chembl3186475
94. Wln: Qy1 & 2q
95. (s)-(+)-1,3-butane Diol
96. 1,3-butanediol [hsdb]
97. 1,3-butandiol [who-dd]
98. Hy-77490ar
99. 1,3-butanediol, (.+/-.)-
100. 1,3-butylene Glycol [mi]
101. Nsc-6966
102. 1,3-butylene Glycol [fcc]
103. Tox21_202408
104. Tox21_300085
105. 1,3 Butylene Glycol [fhfi]
106. Bbl037424
107. Butane-1,3-diol [usp-rs]
108. Hy-77490a
109. Stl483070
110. Akos000119043
111. Db14110
112. Fb31081
113. Msk002151-100m
114. Sb44648
115. Sb44659
116. Sb83779
117. Ncgc00247900-01
118. Ncgc00247900-02
119. Ncgc00253944-01
120. Ncgc00259957-01
121. Sy009940
122. 1,3 Butylene Glycol, (+/-)-
123. Db-000434
124. Db-011642
125. (+/-)-1,3-butanediol, Analytical Standard
126. B0679
127. B3770
128. Cs-0115644
129. Ns00008159
130. En300-19320
131. (+/-)-1,3-butanediol, Anhydrous, >=99%
132. C20335
133. D10695
134. F82621
135. 1,3-butanediol Solution In Methanol, 100ug/ml
136. F099380
137. Q161496
138. (+/-)-1,3-butanediol, Reagentplus(r), 99.5%
139. (+/-)-1,3-butanediol, Reagentplus(r), >=99.0%
140. (+/-)-1,3-butanediol, Saj First Grade, >=98.0%
141. (+/-)-1,3-butanediol, Vetec(tm) Reagent Grade, 98%
142. F8880-3340
143. Butane-1,3-diol, United States Pharmacopeia (usp) Reference Standard
144. 55251-78-0
| Molecular Weight | 90.12 g/mol |
|---|---|
| Molecular Formula | C4H10O2 |
| XLogP3 | -0.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 2 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 40.5 |
| Heavy Atom Count | 6 |
| Formal Charge | 0 |
| Complexity | 28.7 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
/EXP THER/ This study examined the effect of 1,3-butanediol on the selective loss of CA1 pyramidal neurons following a short period of near-complete forebrain ischemia. Injection of 55 mmol 1,3-butanediol/kg body weight at 24 h of recirculation and again at 36 hr following 10 min of forebrain ischemia markedly reduced damage to CA1 neurons examined at 72 hr of recirculation compared with that in saline-treated rats. Comparable treatment with ethanol did not cause significant protection. Neuronal loss was also not reduced by 1,3-butanediol treatment when the ischemic period was extended to 15 min or by single treatments at 24 hr or 36 hr following 10 min of ischemia. However, a single treatment 5 min after reversal of 10 min of ischemia was effective in ameliorating cell loss. The difference in effectiveness of 1,3-butanediol following 10 min and 15 min of ischemia is consistent with a number of previous studies, indicating that the processes leading to loss of CA1 neurons are modified when the ischemic period is extended. Previous findings that 1,3-butanediol reduced damage in other ischemia-susceptible neuronal subpopulations but not in CA1 neurons most likely reflected the longer period of ischemia which was used. The results of the present investigation demonstrate that administration of 1,3-butanediol offers a novel approach for interfering with post-ischemic loss of CA1 neurons following a brief ischemic period which is effective even when initiated after prolonged recirculation periods.
PMID:7859074 Sims NR et al; Brain Res. 662(1-2):216-22 (1994)
/EXP THER/ The biochemical effect of S-1,3-butanediol on streptozotocin induced diabetic rats was studied. Rats were made diabetic by the intraperitoneal injection of 40 mg/kg body weight streptozotocin in sodium citrate buffer. A dosage of 25 mmol/kg body weight of S-1,3-butanediol was injected intraperitoneally for treatment. The streptozotocin induced diabetic rats showed a marked increase in blood glucose level, and significant increase in the level of cholesterol, triglycerides and free fatty acids. The glycogen levels in liver and kidney were greatly decreased in diabetic rats. Treatment with butanediol normalized the glucose and glycogen level but had no significant effect on protein and lipid levels.
Meenakshi C et al; Indian J Physiol Pharmacol. 1995 Apr;39(2):145-8
/EXP THER/ We previously showed that intrastriatal administration of aminooxyacetic acid (AOAA) produces striatal lesions by a secondary excitotoxic mechanism associated with impairment of oxidative phosphorylation. In the present study, we show that and the specific complex I inhibitor rotenone produces a similar neurochemical profile in the striatum, consistent with an effect of AOAA on energy metabolism. Lesions produced by AOAA were dose-dependently blocked by MK-801, with complete protection against GABA and substance P depletions at a dose of 3 mg/kg. AOAA lesions were significantly attenuated by pretreatment with either 1,3-butanediol or coenzyme Q10, two compounds which are thought to improve energy metabolism. These results provide further evidence that AOAA produces striatal excitotoxic lesions as a consequence of energy depletion and they suggest therapeutic strategies which may be useful in neurodegenerative diseases.
PMID:7824183 Brouillet E et al; Neurosci Lett 177(1-2):58-62 (1994)
/EXP THER/ In order to assess the therapeutic value of 1,3 butanediol in ethylene glycol toxicosis, mixed-bred dogs were given an oral dose of commercial antifreeze at 6 mL/kg of body weight (0 hour) and treated (IV) 7 times at 6-hour intervals with 5.5 mL/kg of body weight 1,3 butanediol solution (20% in physiological saline solution) beginning at 8, 12, and 21 hours. Serum glycolic acid concentration was quantitated by high-pressure liquid chromatography. Three dogs that were given ethylene glycol, but no 1,3 butanediol treatment, died with elevated serum glycolic acid concentrations. Five dogs were given ethylene glycol and 1,3 butanediol treatment. Of 2 dogs treated at 8 hours, 1 survived and 1 died at 39 hours; 1 treated at 12 hours and 1 treated at 21 hours survived; 1 dog died soon (27 hours) after treatment was initiated at 21 hours. Four of the 5 dogs had dramatically decreased serum glycolic acid concentrations after 1,3 butanediol treatment, indicating its effectiveness in inhibiting alcohol dehydrogenase-dependent glycolic acid formation in vivo.
Murphy MJ et al; Am J Vet Res. 45(11):2293-5 (1984)
/EXP THER/ Pre-partum feeding of 1,3-butanediol to sows has been shown to improve the metabolic status and survival rate of neonatal pigs. To evaluate the efficacy of short-term, pre-partum feeding of 1,3-butanediol on pig and sow productivity on a large scale and low concentration was the focus of the research. The secondary objective was to determine if pre-partum feeding of 1,3-butanediol had any effect on survival rate and weight gain of lesser body weight pigs, sow body weight and subsequent sow reproductive performance. In a large commercial unit, 2537 sows were fed one of two pre-partum diets (0% or 4.55% 1,3-butanediol) on Day 108+/-3 of pregnancy. 1,3-butanediol provided 8% of the total metabolizable energy. Pigs born live in those litters were equalized by cross-fostering among sows receiving the same pre-partum diet. Pigs were weaned from the sows at 16+/-3 days post-partum and return of sows to estrus and conception rates were determined. Pre-partum feeding of 1,3-butanediol reduced (P=0.01) pre-weaning pig mortalities from 1.44 to 1.24 pigs per litter. The reduction in pig mortality was independent of length of 1,3-butanediol feeding (4 to 11 days). In a subset of 750 litters, four lesser birth-weight pigs from each litter were tagged and monitored to determine the effect of 1,3-butanediol on survival rates and pre-weaning weight gain of pigs with the greatest mortality risk. 1,3-butanediol reduced (P=0.01) pre-weaning mortality of these low birth weight pigs by 5.27%. Based on these data, short-term pre-partum feeding of 1,3-butanediol effectively improves pre-weaning pig productivity at a lower concentration than previously reported.
Stahly TS et al; Anim Reprod Sci. 148 (3-4):145-52 (2014)
Butanediol is metabolized by the liver... beta-hydroxybutyric acid /a main metabolite/ is further metabolized in the tricarboxylic acid cycle to carbon dioxide, which accounts for about 90% of the dose administered. In other studies... in which rats were fed 1,3-butanediol for 3 to 7 weeks, it was found that the blood level of beta-hydroxybutyrate, was also higher than normal.
Bingham, E.; Cohrssen, B.; Powell, C.H.; Patty's Toxicology Volumes 1-9 5th ed. John Wiley & Sons. New York, N.Y. (2001)., p. V7 45
R- and S-1,3-butylene glycol are taken up by the isolated liver of fed or starved rats at the same rate. R-1,3-butylene glycol is mainly transformed to the physiological ketone bodies R-3-hydroxybutyrate and acetoacetate. Only 29-38&% of the S-enantiomer are converted into physiological ketone bodies. The S-enantiomer is further metabolised to S-3-hydroxybutyrate (not a natural compound), lipids and carbon dioxide. Based on these results it can be concluded that the test item is metabolised via physiological pathways, suggesting that it has a low potential to accumulate.
ECHA; REACH Registration for butane-1,3-diol (CAS 107-88-0); Available from, as of November 5, 2015: https://echa.europa.eu/
ABOUT THIS PAGE
Contact Us!
